BMRN vs. HALO: BioMarin Pharmaceutical vs. Halozyme Therapeutics Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BMRN | HALO |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Halozyme Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.85 billion USD | 11.81 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | March 16, 2004 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | HALO |
|---|---|---|
| Total Return (1Y) | 8.82% | 50.94% |
| Total Return (3Y, Annualized) | -12.54% | 41.08% |
| Total Return (5Y, Annualized) | -7.51% | 21.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BMRN | HALO |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 41.19% |
| Beta (5Y) | 0.24 | 0.96 |
| Max Drawdown (5Y) | -57.64% | -49.06% |
| Avg. Volume (3M) | 2.28M | 2.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | HALO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 1.13 |
| Sortino Ratio (1Y) | 0.23 | 1.78 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Halozyme Therapeutics (HALO) reports 216.38%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Halozyme Therapeutics (HALO) reports 26.93%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at 26.58% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BMRN | HALO |
|---|---|---|
| ROE (TTM) | -0.31% | 216.38% |
| ROA (TTM) | 3.89% | 22.42% |
| Net Margin (TTM) | -0.52% | 26.93% |
| Operating Margin (TTM) | 26.58% | 59.84% |
| Gross Margin (TTM) | 53.21% | 77.74% |
Growth
Revenue Growth
Both BioMarin Pharmaceutical (BMRN) at 12.87% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both BioMarin Pharmaceutical (BMRN) at -18.55% and Halozyme Therapeutics (HALO) at -25.36% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | BMRN | HALO |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | 37.55% |
| Revenue Growth (3Y CAGR) | 15.40% | 28.38% |
| EPS Growth (YoY) | -18.55% | -25.36% |
| EPS Growth (3Y CAGR) | 33.89% | 21.14% |
Financial Strength
Current Ratio (MRQ)
Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: BioMarin Pharmaceutical (BMRN) carries debt-to-equity ratio of 0.67 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
Financial Strength Metrics
| Metric | BMRN | HALO |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 3.88 |
| Debt / Equity (MRQ) | 0.67 | -- |
| Net Debt / EBITDA | 4.04 | 1.90 |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | HALO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Halozyme Therapeutics (HALO) trades at 25.91 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile BioMarin Pharmaceutical (BMRN) reports 1.73, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
Valuation Metrics
| Metric | BMRN | HALO |
|---|---|---|
| P/E Ratio (TTM) | -- | 25.91 |
| P/S Ratio (TTM) | 2.97 | 6.55 |
| P/B Ratio (MRQ) | 1.73 | -213.67 |
| Free Cash Flow Yield (TTM) | -0.15% | 3.48% |